AlphaMark Advisors LLC Sells 306 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

AlphaMark Advisors LLC decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 6.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,652 shares of the pharmaceutical company’s stock after selling 306 shares during the quarter. Vertex Pharmaceuticals comprises approximately 0.7% of AlphaMark Advisors LLC’s investment portfolio, making the stock its 25th biggest holding. AlphaMark Advisors LLC’s holdings in Vertex Pharmaceuticals were worth $2,164,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. GHP Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $29,000. Annapolis Financial Services LLC bought a new stake in shares of Vertex Pharmaceuticals in the first quarter worth about $27,000. Stephens Consulting LLC acquired a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $31,000. Founders Capital Management lifted its holdings in shares of Vertex Pharmaceuticals by 50.0% during the 2nd quarter. Founders Capital Management now owns 75 shares of the pharmaceutical company’s stock valued at $35,000 after purchasing an additional 25 shares in the last quarter. Finally, ZRC Wealth Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the 1st quarter valued at approximately $39,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Scotiabank started coverage on shares of Vertex Pharmaceuticals in a research note on Wednesday. They issued a “sector perform” rating and a $480.00 price target on the stock. Piper Sandler upped their target price on shares of Vertex Pharmaceuticals from $500.00 to $535.00 and gave the stock an “overweight” rating in a research note on Friday, August 2nd. Wells Fargo & Company lifted their price target on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research note on Monday, June 24th. HC Wainwright upped their price objective on Vertex Pharmaceuticals from $500.00 to $600.00 and gave the stock a “buy” rating in a research report on Monday, August 5th. Finally, StockNews.com lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday, August 5th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat.com, Vertex Pharmaceuticals presently has an average rating of “Hold” and an average target price of $492.92.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Sangeeta N. Bhatia sold 646 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the transaction, the director now directly owns 4,435 shares in the company, valued at approximately $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Reshma Kewalramani sold 15,202 shares of the stock in a transaction that occurred on Monday, July 22nd. The stock was sold at an average price of $497.00, for a total transaction of $7,555,394.00. Following the sale, the chief executive officer now owns 106,172 shares of the company’s stock, valued at $52,767,484. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Sangeeta N. Bhatia sold 646 shares of Vertex Pharmaceuticals stock in a transaction on Friday, August 30th. The shares were sold at an average price of $500.00, for a total value of $323,000.00. Following the completion of the transaction, the director now directly owns 4,435 shares of the company’s stock, valued at $2,217,500. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 29,487 shares of company stock valued at $14,657,149. 0.20% of the stock is currently owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 2.4 %

Shares of VRTX opened at $498.73 on Friday. The firm has a market cap of $128.72 billion, a P/E ratio of -245.68 and a beta of 0.40. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.26 and a current ratio of 2.52. Vertex Pharmaceuticals Incorporated has a 52 week low of $341.90 and a 52 week high of $510.64. The firm’s 50-day simple moving average is $474.92 and its 200 day simple moving average is $459.08.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Thursday, August 1st. The pharmaceutical company reported ($12.83) earnings per share for the quarter, missing analysts’ consensus estimates of ($12.54) by ($0.29). The firm had revenue of $2.65 billion for the quarter, compared to the consensus estimate of $2.66 billion. Vertex Pharmaceuticals had a negative return on equity of 2.45% and a negative net margin of 4.74%. Vertex Pharmaceuticals’s revenue for the quarter was up 6.1% on a year-over-year basis. During the same quarter last year, the business posted $3.53 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post -2.14 earnings per share for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.